A genetic framework for improving arrhythmia therapy (original) (raw)

• Zheng, Z. J., Croft, J. B., Giles, W. H. & Mensah, G. A. Sudden cardiac death in the United States, 1989 to 1998. Circulation 104, 2158–2163 (2001).
  CAS PubMed Google Scholar
• Vreede-Swagemakers, J. J. M. et al. Out-of-hospital cardiac arrest in the 1990s — A population-based study in the Maastricht area on incidence, characteristics and survival. J. Am. Coll. Cardiol. 30, 1500–1505 (1997).
  PubMed Google Scholar
• Huikuri, H. V., Castellanos, A. & Myerburg, R. J. Sudden death due to cardiac arrhythmias. N. Engl. J. Med. 345, 1473–1482 (2001).
  CAS PubMed Google Scholar
• Page, R. L. & Roden, D. M. Drug therapy for atrial fibrillation: where do we go from here? Nature Rev. Drug Discov. 4, 899–910 (2005).
  CAS Google Scholar
• Nattel, S. & Carlsson, L. Innovative approaches to anti-arrhythmic drug therapy. Nature Rev. Drug Discov. 5, 1034–1049 (2006).
  CAS Google Scholar
• Haissaguerre, M. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 339, 659–666 (1998).
  CAS PubMed Google Scholar
• Darbar, D. et al. Familial atrial fibrillation is a genetically heterogeneous disorder. J. Am. Coll. Cardiol. 41, 2185–2192 (2003).
  PubMed Google Scholar
• Fox, C. S. et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. J. Am. Med. Assoc. 291, 2851–2855 (2004).
  CAS Google Scholar
• Yao, J. A. et al. Remodeling of gap junctional channel function in epicardial border zone of healing canine infarcts. Circ. Res. 92, 437–443 (2003).
  CAS PubMed Google Scholar
• Benjamin, E. J. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. J. Am. Med. Assoc. 271, 840–844 (1994).
  CAS Google Scholar
• Allessie, M. A. et al. Pathophysiology and prevention of atrial fibrillation. Circulation 103, 769–777 (2001).
  CAS PubMed Google Scholar
• Anyukhovsky, E. P. et al. Age-associated changes in electrophysiologic remodeling: a potential contributor to initiation of atrial fibrillation. Cardiovasc. Res. 66, 353–363 (2005).
  CAS PubMed Google Scholar
• Spach, M. S. Mounting evidence that fibrosis generates a major mechanism for atrial fibrillation. Circ. Res. 101, 743–745 (2007).
  CAS PubMed Google Scholar
• Wijffels, M. C., Kirchhof, C. J., Dorland, R. & Allessie, M. A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92, 1954–1968 (1995). This paper was the first to describe the finding that rapid atrial pacing remodels the atrium and thereby predisposes individuals to atrial fibrillation.
  CAS PubMed Google Scholar
• Wijffels, M. C., Kirchhof, C. J., Dorland, R., Power, J. & Allessie, M. A. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 96, 3710–3720 (1997).
  CAS PubMed Google Scholar
• Yue, L., Melnyk, P., Gaspo, R., Wang, Z. & Nattel, S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ. Res. 84, 776–784 (1999).
  CAS PubMed Google Scholar
• Nattel, S. New ideas about atrial fibrillation 50 years on. Nature 415, 219–226 (2002).
  ADS CAS PubMed Google Scholar
• Dobrev, D. & Ravens, U. Remodeling of cardiomyocyte ion channels in human atrial fibrillation. Basic Res. Cardiol. 98, 137–148 (2003).
  PubMed Google Scholar
• Dun, W., Chandra, P., Danilo, P. Jr, Rosen, M. R. & Boyden, P. A. Chronic atrial fibrillation does not further decrease outward currents. It increases them. Am. J. Physiol. Heart Circ. Physiol. 285, H1378–H1384 (2003).
  CAS PubMed Google Scholar
• Kumagai, K. et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J. Am. Coll. Cardiol. 41, 2197–2204 (2003).
  CAS PubMed Google Scholar
• Nakano, Y. et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J. Am. Coll. Cardiol. 43, 818–825 (2004).
  CAS PubMed Google Scholar
• Cardin, S. et al. Contrasting gene expression profiles in two canine models of atrial fibrillation. Circ. Res. 100, 425–433 (2007).
  CAS PubMed Google Scholar
• Nerheim, P., Birger-Botkin, S., Piracha, L. & Olshansky, B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 110, 247–252 (2004).
  PubMed Google Scholar
• Han, W., Chartier, D., Li, D. & Nattel, S. Ionic remodeling of cardiac Purkinje cells by congestive heart failure. Circulation 104, 2095–2100 (2001).
  CAS PubMed Google Scholar
• Akar, F. G., Spragg, D. D., Tunin, R. S., Kass, D. A. & Tomaselli, G. F. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ. Res. 95, 717–725 (2004).
  CAS PubMed Google Scholar
• Frey, N., Katus, H. A., Olson, E. N. & Hill, J. A. Hypertrophy of the heart: a new therapeutic target? Circulation 109, 1580–1589 (2004).
  PubMed Google Scholar
• Schwartz, P. J. The congenital long QT syndromes from genotype to phenotype: clinical implications. J. Intern. Med. 259, 39–47 (2006).
  CAS PubMed Google Scholar
• Ashrafian, H. & Watkins, H. Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications cardiomyopathies: therapeutics based on molecular phenotype. J. Am. Coll. Cardiol. 49, 1251–1264 (2007).
  CAS PubMed Google Scholar
• Sen-Chowdhry, S. et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 115, 1710–1720 (2007).
  PubMed Google Scholar
• Schwartz, P. J., Priori, S. G. & Napolitano, C. How really rare are rare diseases?: the intriguing case of independent compound mutations in the long QT syndrome. J. Cardiovasc. Electrophysiol. 14, 1120–1121 (2003).
  PubMed Google Scholar
• Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 84, 1831–1851 (1991). The Sicilian Gambit group popularized the idea that antiarrhythmic therapies would be most effective if targeted against specific underlying mechanisms.
• Gollob, M. H. et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N. Engl. J. Med. 354, 2677–2688 (2006). This report raised the intriguing possibility of arrhythmias as a manifestation of somatic mutations rather than germline mutations.
  CAS PubMed Google Scholar
• Niimura, H. et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N. Engl. J. Med. 338, 1248–1257 (1998).
  CAS PubMed Google Scholar
• Watkins, H. et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N. Engl. J. Med. 326, 1108–1114 (1992).
  CAS PubMed Google Scholar
• Moss, A. J. et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 115, 2481–2489 (2007).
  CAS PubMed PubMed Central Google Scholar
• Crotti, L. et al. The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds. Toward a mutation-specific risk stratification. Circulation 116, 2366–2375 (2007).
  CAS PubMed Google Scholar
• Priori, S. G., Napolitano, C. & Schwartz, P. J. Low penetrance in the long-QT syndrome: clinical impact. Circulation 99, 529–533 (1999).
  CAS PubMed Google Scholar
• Jouven, X., Desnos, M., Guerot, C. & Ducimetiere, P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 99, 1978–1983 (1999).
  CAS PubMed Google Scholar
• Friedlander, Y. et al. Family history as a risk factor for primary cardiac arrest. Circulation 97, 155–160 (1998).
  CAS PubMed Google Scholar
• Dekker, L. R. C. et al. Familial sudden death is an important risk factor for primary ventricular fibrillation: A case-control study in acute myocardial infarction patients. Circulation 114, 1140–1145 (2006). Refs 37–40 identify a family history of SCD as a potent risk factor for SCD.
  PubMed Google Scholar
• Splawski, I. et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 297, 1333–1336 (2002).
  ADS CAS PubMed Google Scholar
• Ellinor, P. T. & Macrae, C. A. The genetics of atrial fibrillation. J. Cardiovasc. Electrophysiol. 14, 1007–1009 (2003).
  PubMed Google Scholar
• Darbar, D., Hardy, A., Haines, J. L. & Roden, D. M. A novel locus on chromosome 5 for familial atrial fibrillation associated with prolonged signal-averaged p-wave. J. Am. Coll. Cardiol. (in the press).
• Gudbjartsson, D. F. et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 448, 353–357 (2007).
  ADS CAS PubMed Google Scholar
• Mommersteeg, M. T. M. et al. Pitx2c and Nkx2-5 are required for the formation and identity of the pulmonary myocardium. Circ. Res. 101, 902–909 (2007).
  CAS PubMed Google Scholar
• Arking, D. E. et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nature Genet. 38, 644–651 (2006).
  CAS PubMed Google Scholar
• Aarnoudse, A. J. et al. Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam study. Circulation 116, 10–16 (2007).
  PubMed Google Scholar
• Post, W. et al. Associations between genetic variants in the NOS1AP (CAPON) gene and cardiac repolarization in the Old Order Amish. Hum. Hered. 64, 214–219 (2007).
  CAS PubMed PubMed Central Google Scholar
• Lehnart, S. E. et al. Inherited arrhythmias: A National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation 116, 2325–2345 (2007).
  CAS PubMed Google Scholar
• Lehnart, S. & Marks, A. R. Regulation of ryanodine receptors in the heart. Circ. Res. 101, 746–749 (2007).
  CAS PubMed Google Scholar
• Priori, S. G. et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103, 196–200 (2001).
  CAS PubMed Google Scholar
• Lahat, H. et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am. J. Hum. Genet. 69, 1378–1384 (2001).
  CAS PubMed PubMed Central Google Scholar
• Cerrone, M. et al. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor (RyR2). Circ. Res. 96, e77–e82 (2005).
  CAS PubMed Google Scholar
• Knollmann, B. C. et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J. Clin. Invest. 116, 2510–2520 (2006).
  CAS PubMed PubMed Central Google Scholar
• Chopra, N. et al. Modest reductions of cardiac calsequestrin increase sarcoplasmic reticulum Ca2+ leak independent of luminal Ca2+ and trigger ventricular arrhythmias in mice. Circ. Res. 101, 617–626 (2007).
  CAS PubMed Google Scholar
• Vest, J. A. et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 111, 2025–2032 (2005).
  CAS PubMed Google Scholar
• Wehrens, X. H. et al. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc. Natl Acad. Sci. USA 103, 511–518 (2006).
  ADS CAS PubMed Google Scholar
• Marx, S. O. et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101, 365–376 (2000).
  CAS PubMed Google Scholar
• Reiken, S. R. et al. Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts: role of phosphatases and response to isoproterenol. J. Biol. Chem. 278, 444–453 (2002).
  PubMed Google Scholar
• Wehrens, X. H. et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304, 292–296 (2004).
  ADS CAS PubMed Google Scholar
• Benkusky, N. A. et al. Intact beta-adrenergic response and unmodified progression toward heart failure in mice with genetic ablation of a major protein kinase A phosphorylation site in the cardiac ryanodine receptor. Circ. Res. 101, 819–829 (2007).
  CAS PubMed Google Scholar
• Xiao, J. et al. Removal of FKBP12.6 does not alter the conductance and activation of cardiac ryanodine receptor and the susceptibility to stress-induced ventricular arrhythmias. J. Biol. Chem. 282, 34828–34838 (2007).
  CAS PubMed PubMed Central Google Scholar
• Hunt, D. J. et al. K201 (JTV519) suppresses spontaneous Ca2+ release and [3H]ryanodine binding to RyR2 irrespective of FKBP12.6 association. Biochem. J. 404, 431–438 (2007).
  CAS PubMed PubMed Central Google Scholar
• Spirito, P., Seidman, C. E., McKenna, W. J. & Maron, B. J. The management of hypertrophic cardiomyopathy. N. Engl. J. Med. 336, 775–785 (1997).
  CAS PubMed Google Scholar
• Knollmann, B. C. et al. Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling. Circ. Res. 92, 428–436 (2003).
  CAS PubMed Google Scholar
• Sirenko, S.G., Potter, J. D. & Knollmann, B. C. Differential effect of troponin T mutations on the inotropic responsiveness of mouse hearts — role of myofilament Ca2+ sensitivity increase. J. Physiol. 575, 201–213 (2006).
  CAS PubMed PubMed Central Google Scholar
• Ai, X., Curran, J. W., Shannon, T. R., Bers, D. M. & Pogwizd, S. M. Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure. Circ. Res. 97, 1314–1322 (2005).
  CAS PubMed Google Scholar
• Curran, J., Hinton, M. J., Rios, E., Bers, D. M. & Shannon, T. R. Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ. Res. 100, 391–398 (2007).
  CAS PubMed Google Scholar
• Anderson, M. E. et al. KN-93, an inhibitor of multifunctional Ca2+/calmodulin dependent protein kinase, decreases early afterdepolarizations in rabbit heart. J. Pharmacol. Exp.Ther. 287, 996–1006 (1998).
  CAS PubMed Google Scholar
• Mazur, A., Roden, D. M. & Anderson, M. E. Systemic administration of calmodulin antagonist W-7 or protein kinase A inhibitor H-8 prevents torsade de pointes in rabbits. Circulation 100, 2437–2442 (1999).
  CAS PubMed Google Scholar
• Bers, D. M. Beyond beta blockers. Nature Med. 11, 379–380 (2005).
  CAS PubMed Google Scholar
• Zhang, R. et al. Calmodulin kinase II inhibition protects against structural heart disease. Nature Med. 11, 409–417 (2005). This paper reports that transgenic mice expressing a CaMKII-inhibitory peptide were protected against post-myocardial-infarction remodelling and arrhythmias.
  ADS CAS PubMed Google Scholar
• Khoo, M. S. et al. Death, cardiac dysfunction and arrhythmias due to up-regulation of calmodulin kinase II in calcineurin-induced cardiomyopathy. Circulation 114, 1352–1359 (2006).
  CAS PubMed Google Scholar
• Sasano, T., McDonald, A. D., Kikuchi, K. & Donahue, J. K. Molecular ablation of ventricular tachycardia after myocardial infarction. Nature Med. 12, 1256–1258 (2006).
  CAS PubMed Google Scholar
• Bucchi, A. et al. Wild-type and mutant HCN channels in a tandem biological-electronic cardiac pacemaker. Circulation 114, 992–999 (2006).
  PubMed Google Scholar
• Mcanulty, J. et al. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N. Engl. J. Med. 337, 1576–1583 (1997).
  Google Scholar
• Moss, A. J. et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346, 877–883 (2002). This was the first report from a large trial showing that prophylactic implantation of ICDs in patients at high risk for future cardiac arrest reduces mortality.
  PubMed Google Scholar
• Bardy, G. H. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352, 225–237 (2005).
  CAS PubMed Google Scholar
• Spooner, P. M. et al. Sudden cardiac death, genes, and arrhythmogenesis: consideration of new population and mechanistic approaches from a national heart, lung, and blood institute workshop, part I. Circulation 103, 2361–2364 (2001).
  CAS PubMed Google Scholar
• Young, J. B. et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. J. Am. Med. Assoc. 289, 2685–2694 (2003).
  Google Scholar
• The CAST Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. 321, 406–412 (1989). This report shows that Na+-channel-blocking drugs increase mortality in patients convalescing from acute myocardial infarction.
• Krishnan, S.C. & Antzelevitch, C. Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? Circulation 87, 562–572 (1993).
  CAS PubMed Google Scholar
• Lukas, A. & Antzelevitch, C. Differences in the electrophysiological response of canine ventricular epicardium and endocardium to ischemia. Role of the transient outward current. Circulation 88, 2903–2915 (1993).
  CAS PubMed Google Scholar
• Coromilas, J., Saltman, A. E., Waldecker, B., Dillon, S. M. & Wit, A. L. Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. Circulation 91, 2245–2263 (1995).
  CAS PubMed Google Scholar
• Waldo, A. L. et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 348, 7–12 (1996).
  CAS PubMed Google Scholar
• Kober, L. et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Lancet 356, 2052–2058 (2000).
  CAS PubMed Google Scholar
• Camm, A. J. et al. Mortality in patients after a recent myocardial infarction: A randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 109, 990–996 (2004).
  PubMed Google Scholar
• Roden, D. M. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350, 1013–1022 (2004).
  CAS PubMed Google Scholar
• Norwegian Multicenter Study Group. Timolol-induced reduction in mortality in reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 304, 801–807 (1981).
• Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. J. Am. Med. Assoc. 247, 1707–1714 (1982).
• Murray, K. T., Mace, L. C. & Yang, Z. Nonantiarrhythmic drug therapy for atrial fibrillation. Heart Rhythm. 4, S88–S90 (2007).
  Google Scholar
• Li, D. et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104, 2608–2614 (2001).
  CAS PubMed Google Scholar
• Pedersen, O. D., Bagger, H., Kober, L. & Torp-Pedersen, C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100, 376–380 (1999).
  CAS PubMed Google Scholar
• Vermes, E. et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation 107, 2926–2931 (2003).
  PubMed Google Scholar
• Kumagai, K., Nakashima, H. & Saku, K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc. Res. 62, 105–111 (2004).
  CAS PubMed Google Scholar
• Shiroshita-Takeshita, A., Schram, G., Lavoie, J. & Nattel, S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110, 2313–2319 (2004).
  CAS PubMed Google Scholar
• Marchioli, R. et al. Early protection against sudden death by _n_–3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105, 1897–1903 (2002). The greatest reduction in the incidence of SCD in a large randomized clinical trial has been with fish oil (53% reduction at 4 months).
  CAS PubMed Google Scholar
• Leaf, A., Kang, J. X., Xiao, Y. F. & Billman, G. E. Clinical prevention of sudden cardiac death by _n_–3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by _n_–3 fish oils. Circulation 107, 2646–2652 (2003).
  PubMed Google Scholar
• Sarrazin, J. F. et al. Reduced incidence of vagally induced atrial fibrillation and expression levels of connexins by _n_–3 polyunsaturated fatty acids in dogs. J. Am. Coll. Cardiol. 50, 1505–1512 (2007).
  CAS PubMed Google Scholar
• Morady, F. Radio-frequency ablation as treatment for cardiac arrhythmias. N. Engl. J. Med. 340, 534–544 (1999).
  CAS PubMed Google Scholar